SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.

IF 8.4 2区医学 Q1 IMMUNOLOGY Emerging Microbes & Infections Pub Date : 2024-12-01 Epub Date: 2024-05-31 DOI:10.1080/22221751.2024.2359004

Qian Wang, Yicheng Guo, Logan T Schwanz, Ian A Mellis, Yiwei Sun, Yiming Qu, Guillaume Urtecho, Riccardo Valdez, Emily Stoneman, Aubree Gordon, Harris H Wang, David D Ho, Lihong Liu

{"title":"SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.","authors":"Qian Wang, Yicheng Guo, Logan T Schwanz, Ian A Mellis, Yiwei Sun, Yiming Qu, Guillaume Urtecho, Riccardo Valdez, Emily Stoneman, Aubree Gordon, Harris H Wang, David D Ho, Lihong Liu","doi":"10.1080/22221751.2024.2359004","DOIUrl":null,"url":null,"abstract":"<p><p>As SARS-CoV-2 continues to spread and mutate, tracking the viral evolutionary trajectory and understanding the functional consequences of its mutations remain crucial. Here, we characterized the antibody evasion, ACE2 receptor engagement, and viral infectivity of the highly mutated SARS-CoV-2 Omicron subvariant BA.2.87.1. Compared with other Omicron subvariants, including EG.5.1 and the current predominant JN.1, BA.2.87.1 exhibits less immune evasion, reduced viral receptor engagement, and comparable infectivity in Calu-3 lung cells. Intriguingly, two large deletions (Δ15-26 and Δ136-146) in the N-terminal domain (NTD) of the spike protein facilitate subtly increased antibody evasion but significantly diminish viral infectivity. Collectively, our data support the announcement by the USA CDC that the public health risk posed by BA.2.87.1 appears to be low.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":null,"pages":null},"PeriodicalIF":8.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11146261/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Emerging Microbes & Infections","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/22221751.2024.2359004","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

As SARS-CoV-2 continues to spread and mutate, tracking the viral evolutionary trajectory and understanding the functional consequences of its mutations remain crucial. Here, we characterized the antibody evasion, ACE2 receptor engagement, and viral infectivity of the highly mutated SARS-CoV-2 Omicron subvariant BA.2.87.1. Compared with other Omicron subvariants, including EG.5.1 and the current predominant JN.1, BA.2.87.1 exhibits less immune evasion, reduced viral receptor engagement, and comparable infectivity in Calu-3 lung cells. Intriguingly, two large deletions (Δ15-26 and Δ136-146) in the N-terminal domain (NTD) of the spike protein facilitate subtly increased antibody evasion but significantly diminish viral infectivity. Collectively, our data support the announcement by the USA CDC that the public health risk posed by BA.2.87.1 appears to be low.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

SARS-CoV-2 Omicron BA.2.87.1 对血清中和的敏感性高于 EG.5.1 和 JN.1。

随着 SARS-CoV-2 的不断传播和变异，追踪病毒的进化轨迹和了解其变异的功能性后果仍然至关重要。在这里，我们描述了高度变异的 SARS-CoV-2 Omicron 亚变体 BA.2.87.1 的抗体逃避、ACE2 受体参与和病毒传染性。与其他 Omicron 亚变体（包括 EG.5.1 和目前占主导地位的 JN.1）相比，BA.2.87.1 在 Calu-3 肺细胞中表现出较低的免疫逃避性、较低的病毒受体参与性和相当的感染性。耐人寻味的是，尖峰蛋白 N 端结构域（NTD）的两个大缺失（Δ15-26 和 Δ136-146）促进了抗体逃避能力的微弱增强，但却显著降低了病毒的感染性。总之，我们的数据支持美国疾病预防控制中心的公告，即 BA.2.87.1 带来的公共卫生风险似乎很低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Emerging Microbes & Infections IMMUNOLOGY-MICROBIOLOGY

CiteScore

26.20

自引率

2.30%

发文量

276

审稿时长

20 weeks

期刊介绍： Emerging Microbes & Infections is a peer-reviewed, open-access journal dedicated to publishing research at the intersection of emerging immunology and microbiology viruses. The journal's mission is to share information on microbes and infections, particularly those gaining significance in both biological and clinical realms due to increased pathogenic frequency. Emerging Microbes & Infections is committed to bridging the scientific gap between developed and developing countries. This journal addresses topics of critical biological and clinical importance, including but not limited to: - Epidemic surveillance - Clinical manifestations - Diagnosis and management - Cellular and molecular pathogenesis - Innate and acquired immune responses between emerging microbes and their hosts - Drug discovery - Vaccine development research Emerging Microbes & Infections invites submissions of original research articles, review articles, letters, and commentaries, fostering a platform for the dissemination of impactful research in the field.